Clene Inc. (CLNN) 10-Q Summary: Quarter Ended June 30, 2026
Business Context and Reporting Period
Clene Inc. is a clinical-stage pharmaceutical company developing clean-surfaced nanotechnology therapeutics for central nervous system disorders, including ALS, MS, and Parkinson's disease. The company generates minimal revenue from dietary supplements sold via a related party, 4Life Research LLC. This report covers the three and six months ended June 30, 2026. The company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended June 30, 2026 | 6 Months Ended June 30, 2026 | 6 Months Ended June 30, 2025 |
|---|---|---|---|
| Total Revenue | $90 | $105 | $108 |
| Net Loss | $(13,424) | $(21,515) | $(8,170) |
| Loss Per Share (Basic/Diluted) | $(1.08) | $(1.79) | $(0.89) |
| Operating Cash Flow | N/A | $(7,116) | $(9,755) |
| Cash and Cash Equivalents (End of Period) | $9,671 | $9,671 | $7,285 |
| Total Debt (Notes & Convertible) | $19,040 | $19,040 | $19,056 |
| Accumulated Deficit | $(329,811) | $(329,811) | $(308,296) |
Note: Total Debt includes current and non-current portions of Notes Payable and Convertible Notes Payable.
Material Changes vs. Prior Period
- Net Loss Expansion: Net loss for the six months ended June 30, 2026, increased by 163% compared to the prior year period, driven primarily by non-cash losses related to fair value adjustments of warrant and derivative liabilities.
- Revenue Stability: Total revenue remained relatively flat ($105k vs. $108k) for the six-month period, with product revenue increasing slightly while royalty revenue declined.
- Operating Expenses: Total operating expenses decreased by 25% year-over-year for the six-month period, largely due to cost-saving initiatives and a reduction in grant revenue recognized as a reduction of expenses.
- Financing Activity: The company raised approximately $13.0 million in gross proceeds from registered direct offerings of equity securities during the six months ended June 30, 2026, compared to $5.0 million in the prior year period.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management has concluded that there is substantial doubt about the company's ability to continue as a going concern for one year from the date of the report. The company expects to incur additional losses and will require additional financing to sustain operations.
- Critical Debt Covenants: The company is required to maintain unrestricted cash and cash equivalents of at least $2.0 million to avoid acceleration of its Senior Secured Convertible Promissory Notes (2024 SSCP Notes).
- Unusual Non-Cash Items: The net loss was significantly impacted by a $5.2 million loss on the change in fair value of common stock warrant liabilities and a $2.6 million loss on the change in fair value of derivative liabilities. Additionally, a $4.6 million loss was recognized on the initial issuance of equity due to the fair value of warrants exceeding proceeds.
- Clinical Outlook: The company intends to submit a New Drug Application (NDA) for CNM-Au8 in ALS in the early fourth quarter of 2026. A Phase 3 RESTORE-ALS trial is planned for initiation in Q2 2027.
- Internal Controls: The company disclosed material weaknesses in internal control over financial reporting, specifically regarding the control environment, manual journal entries, and IT general controls.
Investor Verification Checklist
- Liquidity Runway: Verify if the current cash balance of ~$9.7 million is sufficient to meet the $2.0 million covenant and fund operations until the next anticipated financing or revenue milestone.
- Warrant Liability Volatility: Assess the sensitivity of the $16.1 million warrant liability and $5.7 million derivative liability to changes in the company's stock price, as these significantly impact reported net loss.
- Related Party Dependence: Confirm the stability of revenue from 4Life Research LLC, which accounted for 100% of revenue in the quarter, and the impact of the recent conversion of exclusive rights to non-exclusive rights.
- Debt Structure: Review the terms of the Senior Secured Convertible Promissory Notes, including the 12% interest rate, conversion features, and potential acceleration triggers.
- Remediation of Controls: Monitor the progress of remediation efforts for the identified material weaknesses in internal controls over financial reporting.